Cannabidiol and Alzheimer's disease

Area of Science:

• Neuroscience
• Pharmacology
• Geriatrics

Background:

• Alzheimer's disease (AD) is a leading cause of dementia, affecting millions globally.
• Current treatments include cholinesterase inhibitors and memantine.
• Cannabinoids, particularly Cannabidiol (CBD), are being explored for AD symptom relief based on anecdotal evidence.

Purpose of the Study:

• To evaluate the potential therapeutic effects of Cannabidiol (CBD) in Alzheimer's disease (AD).
• To synthesize pre-clinical and clinical findings on CBD's role in mitigating AD pathology and symptoms.

Main Methods:

• Review of pre-clinical (in vitro) studies on CBD's mechanisms of action.
• Analysis of existing, though limited and low-quality, real-world data and clinical observations.
• Identification of gaps in current clinical evidence, specifically the lack of randomized placebo-controlled trials.

Main Results:

• Pre-clinical studies suggest CBD may reduce cognitive decline, neurodegeneration, oxidative stress, and neuroinflammation.
• CBD has shown potential in promoting neuroplasticity, particularly in the hippocampus.
• Clinical evidence remains conflicting, with no high-quality randomized controlled trials published to date.

Conclusions:

• While pre-clinical data is promising, robust clinical evidence supporting CBD's efficacy in Alzheimer's disease is lacking.
• Further well-designed, randomized placebo-controlled trials are essential to determine the clinical relevance of CBD for AD symptom management.
• The comparative efficacy of CBD against conventional AD treatments requires rigorous investigation.